Genix Pharmaceuticals Corporation Share Price
Stocks
GENX
CA37232A1093
Pharmaceuticals
OTC Markets Traded|
Delayed
Toronto S.E.
14:30:00 27/08/2026 BST
|
5-day change | 1st Jan Change | ||
| 0.0200 CAD | -.--% |
|
-.--% | -20.00% |
| Market Cap | 1.22M 859K 763K 712K 649K 82.57M 1.24M 8.62M 3.34M 42.21M 3.22M 3.15M 135M | P/E 2024 |
-40.5x | P/E 2025 | -5.33x |
|---|---|---|---|---|---|
| Enterprise Value | 2.22M 1.56M 1.39M 1.29M 1.18M 150M 2.24M 15.66M 6.07M 76.66M 5.86M 5.73M 246M | EV / Sales 2024 |
929,496,174x | EV / Sales 2025 | - |
| Free-Float |
53.08% | Yield 2024 * |
-
| Yield 2025 | - |
Toronto S.E.CAD
| Markets | Quality | ||
|---|---|---|---|
Toronto S.E.
| GENX | Delayed | |
OTC Markets
| GENPF | Delayed |
| 3 months | +33.33% | ||
| Current year | -20.00% |
| Current year | 0.02 | 0.02 | |
| 1 year | 0.02 | 0.04 | |
| 3 years | 0.02 | 0.09 | |
| 5 years | 0.02 | 0.19 | |
| 10 years | 0.01 | 0.3 |
| Manager | Title | Age | Since |
|---|---|---|---|
Sina Pirooz
CEO | Chief Executive Officer | 57 | 02/08/2018 |
Raylen Tamayo
DFI | Director of Finance/CFO | - | 03/05/2026 |
Mahmoud Aziz
PSD | President | - | 20/05/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Sina Pirooz
BRD | Director/Board Member | 57 | 02/08/2018 |
Jamie Lewin
BRD | Director/Board Member | 76 | 10/03/2019 |
Kevin Bottomley
BRD | Director/Board Member | 48 | 04/09/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 09/09/25 | Option | Chairman | 1,000,000 | 1.6885% | ||
| 09/09/25 | Option | Chairman | 1,000,000 | 1.6885% | ||
| 09/09/25 | Option | Chief Executive Officer | 1,000,000 | 1.6885% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -.--% | -.--% | -33.33% | -50.00% | 859K | ||
| +1.16% | -3.43% | +36.07% | +115.04% | 1,019B | ||
| -0.77% | -5.60% | +35.72% | +64.63% | 617B | ||
| -0.84% | -0.58% | +12.36% | +77.95% | 464B | ||
| -2.33% | -3.01% | +61.79% | +41.24% | 356B | ||
| +0.52% | -2.08% | +20.67% | +41.06% | 333B | ||
| +0.10% | -3.36% | +10.89% | +34.50% | 267B | ||
| -0.59% | -4.92% | -6.66% | +8.95% | 244B | ||
| -0.68% | -2.79% | +35.30% | +51.84% | 218B | ||
| -0.56% | -4.10% | +28.44% | +93.66% | 179B | ||
| Average | -0.36% | -3.19% | +20.12% | +47.89% | 369.72B | |
| Weighted average by Cap. | -0.14% | -3.54% | +29.08% | +70.63% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 0 0 0 0 0 0.27 0 0.03 0.01 0.14 0.01 0.01 0.45 | - |
| Net income | -73.2K -51.35K -45.62K -42.58K -38.81K -4.94M -73.88K -515K -200K -2.52M -193K -189K -8.1M | -335K -235K -209K -195K -178K -22.59M -338K -2.36M -914K -11.55M -882K -863K -37.07M |
| Net Debt | 804K 564K 501K 468K 426K 54.23M 812K 5.66M 2.19M 27.72M 2.12M 2.07M 88.98M | 999K 701K 623K 581K 530K 67.39M 1.01M 7.03M 2.73M 34.45M 2.63M 2.57M 111M |
Employees
4,000
Sector
Pharmaceuticals
- Stock Market
- Stocks
- GENX Stock
Select your edition
All financial news and data tailored to specific country editions

















